WO2009009152A1 - Rosuvastatin intermediates and their preparation - Google Patents
Rosuvastatin intermediates and their preparation Download PDFInfo
- Publication number
- WO2009009152A1 WO2009009152A1 PCT/US2008/008635 US2008008635W WO2009009152A1 WO 2009009152 A1 WO2009009152 A1 WO 2009009152A1 US 2008008635 W US2008008635 W US 2008008635W WO 2009009152 A1 WO2009009152 A1 WO 2009009152A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mbsg
- rosuvastatin
- tbpo
- purity
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- WBSFJYIYABHYRN-UHFFFAOYSA-N n-[5-(diethoxyphosphorylmethyl)-4-(4-fluorophenyl)-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical class CCOP(=O)(OCC)CC1=C(C(C)C)N=C(N(C)S(C)(=O)=O)N=C1C1=CC=C(F)C=C1 WBSFJYIYABHYRN-UHFFFAOYSA-N 0.000 title claims description 7
- 238000000034 method Methods 0.000 claims abstract description 76
- 230000008569 process Effects 0.000 claims abstract description 67
- 229960000672 rosuvastatin Drugs 0.000 claims abstract description 46
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims abstract description 46
- 239000000543 intermediate Substances 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims description 65
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 claims description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 238000000746 purification Methods 0.000 claims description 16
- 239000010409 thin film Substances 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- 229910052727 yttrium Inorganic materials 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims description 7
- 229960004796 rosuvastatin calcium Drugs 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical class C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- -1 alkyl lithium Chemical compound 0.000 claims description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical group [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical class [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 claims description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical class [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 description 30
- 239000002585 base Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 0 C*(C)N(C)C(NC)=N Chemical compound C*(C)N(C)C(NC)=N 0.000 description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- FFFKSDDUCCGFGT-HXUWFJFHSA-N tert-butyl (3r)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1C=CC(=O)C[C@@H](O)CC(=O)OC(C)(C)C FFFKSDDUCCGFGT-HXUWFJFHSA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- QVCUKHQDEZNNOC-UHFFFAOYSA-N 1,2-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1NC2 QVCUKHQDEZNNOC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZKYFCRMRVJDUET-UHFFFAOYSA-N 2-hydroxy-2,3-dimethylpentanedioic acid Chemical compound OC(=O)CC(C)C(C)(O)C(O)=O ZKYFCRMRVJDUET-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- XFOMRLFJUABWME-SSDOTTSWSA-N 5-o-tert-butyl 1-o-methyl (3r)-3-hydroxypentanedioate Chemical compound COC(=O)C[C@@H](O)CC(=O)OC(C)(C)C XFOMRLFJUABWME-SSDOTTSWSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- WOCOTUDOVSLFOB-UHFFFAOYSA-N CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C=O Chemical compound CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c(cc2)ccc2F)c1C=O WOCOTUDOVSLFOB-UHFFFAOYSA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000007295 Wittig olefination reaction Methods 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- FESAXEDIWWXCNG-UHFFFAOYSA-N diethyl(methoxy)borane Chemical compound CCB(CC)OC FESAXEDIWWXCNG-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- HZJYVUCFRAHZBC-UHFFFAOYSA-N n-methyl-n-(4-propan-2-ylpyrimidin-2-yl)methanesulfonamide Chemical compound CC(C)C1=CC=NC(N(C)S(C)(=O)=O)=N1 HZJYVUCFRAHZBC-UHFFFAOYSA-N 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- XBCOWFFQISKOSJ-OAHLLOKOSA-N tert-butyl (3r)-3-[tert-butyl(dimethyl)silyl]oxy-6-dimethoxyphosphoryl-5-oxohexanoate Chemical compound COP(=O)(OC)CC(=O)C[C@@H](O[Si](C)(C)C(C)(C)C)CC(=O)OC(C)(C)C XBCOWFFQISKOSJ-OAHLLOKOSA-N 0.000 description 1
- IJHZGLLGELSZAF-WOJBJXKFSA-N tert-butyl (3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1C=C[C@@H](O)C[C@@H](O)CC(=O)OC(C)(C)C IJHZGLLGELSZAF-WOJBJXKFSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/4053—Esters of poly(thio)phosphonic acids containing substituents selected from B, Si, P (other than -PO3H2 groups in free or esterified form), or a metal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to new synthesis of Rosuvastatin intermediates.
- Statin drugs are currently the most therapeutically effective drugs available for reducing the level of LDL in the blood stream of a patient at risk for cardiovascular disease.
- statin drugs disrupt the synthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme ("HMG-CoA reductase").
- HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. Consequently, HMG-CoA reductase inhibition leads to a reduction in the rate of formation of cholesterol in the liver.
- Decreased production of cholesterol causes an increase in the number of LDL receptors and corresponding reduction in the concentration of LDL particles in the bloodstream. Reduction in the LDL level in the bloodstream reduces the risk of coronary artery disease. (J. A.M. A. 1984; 251 : 351-74).
- statins include: inter alia, compactin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin and atorvastatin, which are administered in their lactone form, as sodium salts, or as calcium salts.
- Rosuvastatin (7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino) pyrimidin-5-yl]-(3R, 5S)-dihydroxy-(E)-6-heptenoic acid) calcium, an HMG-CoA reductase inhibitor, can lower LDL-cholesterol and triglycerides levels more effectively than first generation statin drugs.
- Rosuvastatin calcium has the following chemical formula:
- PCT publication No. WO 03/087112 discloses the synthesis of rosuvastatin from an intermediate t-butyl (3R)-3-(t-butyldimethylsilyloxy)-6-dimethoxyphosphinyl-5- oxohexanate ("19TBP0").
- This process describes the preparation of t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R)-3-hydroxy-5-oxo-6-heptenate ("TB21”), a key intermediate in the preparation of rosuvastatin, by going through 19TBP0 intermediate.
- the process is illustrated in the following scheme: OH
- rosuvastatin calcium can contain extraneous compounds or impurities that can come from many sources. These can include unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products. Impurities in rosuvastatin or any active pharmaceutical ingredient (API) are undesirable, and, in extreme cases, might even be harmful to a patient being treated with a dosage form of the API in which a sufficient amount of impurities are present.
- API active pharmaceutical ingredient
- the present invention encompasses a non protected hydroxyl group intermediate, 19 OH-XYPO, having the following formula:
- X is O, N, or S
- Y is selected from the group consisting of: a Ci-C 4 alkyl, aryl, and alkyl aryl group, preferably 19 OH-TBPO, having the following formula:
- the present invention encompasses a process for preparing 19 OH-XYPO (particular Iy 19 OH-TBPO), comprising combining a compound, 19-0H-MBSG-XY, having the following formula:
- OH-MBSG preferably OH-MBSG, having the following formula:
- OH-MBSG dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP.
- the present invention provides a process for preparing 19 0H-XYP0 (particularly 19 OH-TBPO) and further converting it to TB21 and/or rosuvastatin and pharmaceutically accepted salts thereof. [0015] In another embodiment the present invention provides a compound,
- OH-MBSG-XY wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C 4 alkyl, aryl, and alkyl aryl group, preferably OH-MBSG, wherein the compound has a purity of at least about 95.5 % as measured by GC method.
- the present invention provides a process for preparing OH-MBSG-XY (particularly OH-MBSG) and further converting it to TB21 and/or rosuvastatin and pharmaceutically accepted salts thereof.
- the present invention also provides a process for purifying OH-MBSG and/or 19 OH-TBPO by using a thin film evaporator, more preferably a thin wiped-f ⁇ lm evaporator
- the present invention encompasses a process for preparing compound TB21 by a Wittig-Horner reaction comprising combining 19 OH-XYPO (particularly 19 OH-TBPO), FPP-aldehyde and a base.
- the present invention encompasses a process for preparing TB21 having the following formula:
- TB21 comprising combining OH-MBSG, dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl group intermediate 19 OH-TBPO; and combining the obtained 19 OH-TBPO with FPP-aldehyde and a base.
- DMMP dimethylmethylphosphonate
- the present invention a process for preparing
- the present invention a process for purifying a one or more of rosuvastatin intermediates 19 OH -XYPO of formula:
- X is O, N, or S
- Y is selected from the group consisting of: a Ci-C 4 alkyl, aryl, and alkyl aryl group comprising applying a force under pressure of less than one atmosphere to increase surface area of a feed containing the intermediate, thereby providing the intermediate in purified form.
- the process comprises feeding the intermediate to a thin film evaporator is used.
- the process comprises feeding the intermediate to a thin film evaporator with wiper blades.
- X is O and Y is t-butyl.
- the present invention a process for preparing
- the term "Wittig-Horner” refers to a condensation reaction of an aldehyde with a phosphonate derivative to create a double bond (also known as a Horner-Wadsworth-Emmons reaction). (See -Maryanoff et al. "The Wittig olefination reaction”, Chem. Rev. (1989) 89, 863-927; Boutagy et al. "Olefin synthesis with organic phosphonate carbanions", Chem. Rev.
- room temperature refers to a temperature of about 20 0 C to about 27°C.
- OH-MBSG refers to (R)-l-tert-butyl 5- methyl 3-hydroxypentanedioate having the following formula:
- FPP-aldehyde refers to 4-(4-fluorophenyl)-
- 6-isopropyl-2-(N-methyl-N-methylsulfonylamino) pyrimidine having the following formula:
- TB21 refers to t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R)-3-hydroxy-5-oxo-6-heptenate, having the following formula:
- TBRE refers to t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R,5S)-3,5-dihydroxy-6-heptenate, having the following formula:
- X is O, N, or S
- Y is selected from the group consisting of: a Ci-C 4 alkyl, aryl, and alkyl aryl group.
- OH-MBSG-XY refers to the compound of formula: wherein X is O, N, or S, and selected from the group consisting of: a Ci-C 4 alkyl, aryl, and alkyl aryl group,
- the present invention encompasses a non protected hydroxyl group intermediate, 19 OH-XYPO having the following structure:
- X O, N, or S
- Y is selected from the group consisting of: a Ci-C 4 alkyl, C 6 -Ci 2 aryl, and C 6 -Ci 2 alkyl aryl group.
- X is O and Y is a C]-C 4 alkyl group, more preferably, Y is a t-butyl ester, providing 19 OH-TBPO, with the following formula:
- 19 OH -XYPO is a key intermediate in the preparation of rosuvastatin calcium.
- the intermediate 19 OH-TBPO is a transparent to yellowish oil that cannot be purified by conventional scalable methods, such as crystallization.
- the invention provides a process for the purification of rosuvastatin intermediates, OH-MBSG-XY (particularly OH-MBSG) and/or 19 OH-XYPO (particularly 19 OH- TBPO), wherein the process is suitable for industrial use, as it does not entail chromatography steps.
- This process includes distilling the impurities of 19 OH-TBPO and OH-TBPO with a thin film evaporator (TFE) device.
- TFE thin film evaporator
- a thin film evaporator allows a temperature increase during the distillation process without decomposition of OH-MBSG-XY (particularly OH- MBSG) and/or 19 OH-XYPO (particularly 19 OH-TBPO), allowing the preparation of pure materials.
- a typical thin-film evaporator comprises of two major assemblies: a heated body and a close-clearance rotor.
- a feed travels to a rotating distributor plate. The feed can be from the top, which would then fall naturally by gravity onto the plate.
- Optional Wiper blades along with centrifugal force, resulting from the rotation of the plate, then create a thin film by distributing the feed, optimally evenly, over the wall. Due to reduced pressure in the plate chamber and the resulting increase, in surface area, the volatile components readily evaporate. The remaining "pure”solid is pushed to the sides by the blades and collected.
- the feed is typically in the form of an oil which is obtained by removing the solvent in which OH-MBSG-XY (particularly OH-MBSG) and/or 19 OH -XYPO (particularly 19 OH-TBPO) is in.
- the feed can also be in the form of a solution.
- the solvent is typically removed in an evaporator, which leaves the oil (without solvent), hi principle, in a scale-up apparatus, these two operations (evaporation of solvent and then purification of the oil) can be done in the TFE.
- the OH-MBSG-XY (particularly OH-MBSG) is purified by the TFE method.
- OH-MBSG-XY (particularly OH-MBSG) is fed into the thin film evaporator, and the evaporation is performed at a temperature of about 130 0 C to about 200 0 C, more preferably of about 150 0 C to about 160 0 C.
- the evaporation is performed under a pressure of about 0 mbar to about 15 mbar, more preferably of about 0.5 mbar to about 5 mbar, yet more preferably of about 0.97 mbar to about 1.2 mbar.
- the OH-MBSG-XY (particularly OH-MBSG) obtained by the thin film evaporation method of the invention has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area by GC.
- the obtained OH-MBSG has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
- the present invention provides OH-MBSG-XY (particularly OH-
- MBSG having a purity of at least about 90%, more preferably of at least about 95 %, and even more preferably of at least about 98 % area by GC.
- OH-MBSG- XY (particularly OH-MBSG)has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area as measured by GC.
- the OH-MBSG-XY (particularly OH-MBSG)has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
- the 19 OH -XYPO (particularly 19 OH-TBPO) is purified by the TFE method.
- 19 OH -XYPO (particularly 19 OH- TBPO) is fed into the thin film evaporator, and the evaporation is performed at a temperature of about 130°C to about 200 0 C, more preferably of about 150°C to about 160°C.
- the evaporation is performed under a pressure of about 0 mbar to about 15 mbar, more preferably of about 0.97 mbar to about 1.2 mbar.
- the OH-MBSG-XY (particularly OH-MBSG) and/or 19
- OH -XYPO (particularly 19 OH-TBPO) obtained by the thin film evaporation method of the invention has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area as measured by GC.
- the obtained 19 OH-TBPO has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
- the present invention provides a process of purifying OH-MBSG-XY
- the 19 OH -XYPO can be prepared by a process comprising combining a compound OH-MBSG-XY (particularly OH-MBSG, having the following formula:
- OH-MBSG dimethylmethylphosphonate
- DMMP dimethylmethylphosphonate
- the process can be carried out by dissolving DMMP in an organic solvent that is inert to a strong base, and adding dropwise or slowly a base that is sufficiently strong to produce a carbanion.
- bases include LDA, sodium or lithium salts of Hexamethyldisilazane, sec-BuLi, tert-BuLi, NaH, KH, KtBuO, NaBuO, and C 4 to Cjo alkyl lithium.
- the organic solvent is selected from the group consisting of: dimethoxyethane ("DME"), hexane, methylene chloride tetrahydrofuran (“THF”) and dioxane.
- the organic solvent is THF, most preferably, dry THF (contains less than 2% water by volume).
- the solution can be cooled, such as to a temperature of about -50°C to about -100°C, more preferably, to a temperature of about -75°C.
- the base capable of making a carbanion on DMMP is preferably BuLi.
- n-BuLi is added to the solution to obtain a reaction mixture.
- the reaction mixture can be maintained at a temperature of about -50 0 C to about -10O 0 C. More preferably, the reaction mixture is maintained at a temperature of about -7O 0 C to about- 100 0 C.
- n-BuLi is dissolved in hexane.
- a base is used to allow formation of the carbanion reaction to occur.
- the base after reaction provide a metal cation (M+) that is selected from the group consisting of lithium, sodium, potassium and cesium. More preferably, M+ is lithium to the base used for the preparation of the phosphonate.
- M+ is lithium to the base used for the preparation of the phosphonate.
- OH-MBSG-XY can be combined with the reaction mixture in 4 portions.
- OH-MBSG-XY is added in intervals of about 5 minutes to about 60 minutes, more preferably, in intervals of about 30 minutes on gram scale.
- the reaction mixture Prior to the addition of OH-MBSG-XY (particularly OH-MBSG), the reaction mixture can be stirred.
- the stirring can be done at a temperature of about - 50°C to about -100°C, more preferably, at a temperature of about -70°C to about - 75 0 C.
- the stirring can be for about 1 hour to about 6 hours, more preferably, for about 3 hours.
- the reaction mixture can be washed to remove impurities.
- the washing can be with the same solvent used during the process.
- reaction mixture After a washing step, if carried out, the reaction mixture can be stirred.
- the stirring is at a temperature of about -50°C to about -100°C. Preferably, at a temperature of about -70 0 C to about -75°C. Preferably, the stirring is for about 2 hours.
- the reaction mixture can be quenched by adding an agent that has an available proton.
- the quenching may be done using water, organic acid or inorganic acid.
- the quenching is with AcOH and EtOAc.
- the reaction mixture can be heated to bring the temperature to about -10 to about 30 0 C, such as about room temperature or a temperature of about 20 0 C, before separation. Water can be added to the heated reaction mixture to obtain a two phase system in order to perform the extraction of 19 OH -XYPO (particularly 19 OH-TBPO).
- the two phases are separated.
- the aqueous phase is extracted.
- the extraction can be done with polar solvents such as CH 2 Cl 2 , Diethylcarbonate, Methyl ethyl ketone, Methyl iso-butyl ketone, cyclopenthylmethylether, t-buteyl methyl ether, diethyl ether, diisopropylether, more preferably with EtOAc (ethyl acetate).
- polar solvents such as CH 2 Cl 2 , Diethylcarbonate, Methyl ethyl ketone, Methyl iso-butyl ketone, cyclopenthylmethylether, t-buteyl methyl ether, diethyl ether, diisopropylether, more preferably with EtOAc (ethyl acetate).
- the organic layer is dried and filtered.
- the drying is done with dehydrating reagent or molecular sieves, more preferably, with a dehydrating reagent.
- the dehydrating reagent is sodium sulfate (Na 2 SO 4 ) or magnesium sulfate (MgSO 4 ), more preferably Na 2 SO 4
- the obtained dried and filtered layer is further concentrated to obtain a residue of 19 OH -XYPO (particularly 19 OH-TBPO).
- the concentration is under a pressure of less than one atmosphere, or a pressure of less than 1 OOmmHg, such as in a vacuum.
- the concentration is done by vacuum distillation.
- the vacuum distillation is done whilst heating, such as to a temperature of about 2O 0 C to about 9O 0 C.
- OH -XYPO is further purified by a thin film evaporator.
- both concentrations of 19 OH -XYPO (particularly 19 OH- TBPO) after extraction and purification could be performed in a TFE.
- 19 OH -XYPO obtained by the processes of the invention may be further used to prepare rosuvastatin and pharmaceutically accepted salts thereof, for example, according to the procedures described in PCT publication No. WO 06/091771.
- the 19 OH -XYPO (particularly 19 OH-TBPO),obtained, optionally by the thin film evaporation purification, can be converted to TB21 (or another ester) by a Wittig-Horner reaction.
- the process for preparing compound TB21 by a Wittig- Horner reaction comprises combining 19 OH-TBPO, FPP-aldehyde and a base,
- 19 OH -XYPO can be dissolved in a dry solvent (contain less than 2% water by volume).
- dry solvents include, but are not limited to, ethereal solvents such as tetrahydrofuran ("THF"), dioxane, dimethoxyethane (“DME”), aromatic solvents such as toluene, chlorinated solvents and acetonitrile. More preferably, the solvent is dry THF.
- the solution can be cooled, such as to a temperature of about -20 0 C to about 1O 0 C, more preferably to about O 0 C.
- Suitable bases for the Wittig-Horner reaction include but are not limited to, metal hydrides, MOMe, MOH, MOtBu, M 2 CO 3 , wherein M can be sodium, potassium, lithium or cesium, BuLi or other lithiated bases, DBU (1,8- diazabicyclo[5.4.0]undec-7-ene), and DABCO (diazabicyclo[2.2.2]octane).
- the base is KOtBu.
- the base is preferably added to the cooled solution to obtain a reaction mixture.
- the base can be added under stirring.
- the reaction mixture can be stirred at a temperature of about -20 0 C to about 40 0 C, more preferably at about O 0 C.
- the reaction mixture can be further stirred.
- the stirring can be for about 1 minute to about 1 hour, more preferably for about 15 minutes.
- FPP-aldehyde is added to the reaction mixture.
- reaction mixture can be stirred, such as at a temperature of about O 0 C to about 6O 0 C, more preferably at about 4O 0 C.
- the mixture can be stirred for about 1 hour to about 12 hours, such as about 7 hours.
- reaction can be quenched, such as by using an acid, including AcOH (acetic acid).
- an acid including AcOH (acetic acid).
- the reaction mixture can be optimized for recovery of the product, by adding water (and optionally brine) and a water immiscible organic solvent such as ethyl acetate to obtain two phases.
- the phases can be then separated.
- the organic phase can be washed such as with water or saturated bicarbonate and brine, hi one embodiment, the washing is done with saturated bicarbonate and brine.
- the remaining solvent is removed to obtain TB21.
- the removal of the solvent is under pressure of less than one atmosphere, such as vacuum (less than lOOmmHg).
- the compound TB21 is under pressure of less than one atmosphere, such as vacuum (less than lOOmmHg).
- TB21 is prepared by a process comprising combining OH-MBSG having the following formula:
- TB21 obtained by the processes of the invention may be further converted to rosuvastatin and pharmaceutically accepted salts thereof.
- the conversion may be done according to PCT publication No. WO 06/091771 and according to US RE37,314.
- the procedure described in PCT publication No. WO 06/091771 includes converting TB21 to rosuvastatin through the intermediate TBRE.
- TBRE is obtained by a reduction of the intermediate TB21 according to the scheme provided below:
- Rosuvastatin may be obtained upon saponification of TBRE according to the scheme provided below:
- Rosuvastatin obtained by the processes of the invention may be further converted to a pharmaceutically acceptable salt of rosuvastatin, preferably the calcium salt.
- a pharmaceutically acceptable salt of rosuvastatin preferably the calcium salt.
- the process of converting rosuvastatin into its pharmaceutically acceptable salt includes contacting rosuvastatin with calcium hydroxide, or with a stronger base such as sodium hydroxide.
- the base is preferably combined dropwise with a reaction mixture of rosuvastatin at a suitable temperature, such as a temperature of about 25°C ⁇ 5°C.
- the reaction mixture may be washed with a suitable water immiscible organic solvent.
- Suitable water immiscible organic solvents include, but are not limited to, hydrocarbons; preferably the water immiscible organic solvent is toluene.
- the water immiscible organic solvent may be removed by phase separation. Remaining water immiscible organic solvent may be removed by distillation of the reaction mixture, preferably at a temperature of about 40 0 C to about 45°C under reduced pressure (below about 50 mmHg).
- Column & Packing DB- 17 30m x 0.53mm l ⁇ m film thickness
- the reaction mixture may then be combined with an alkali metal, including a source of calcium such as calcium chloride or calcium acetate, to form the salt of rosuvastatin.
- a source of calcium such as calcium chloride or calcium acetate
- calcium chloride may be added dropwise to a reaction mixture of rosuvastatin at a suitable temperature, such as a temperature of about 35 0 C to about 45 0 C, and preferably at about 40°C, over a period of about thirty to about ninety minutes.
- Active carbon may be combined with a reaction mixture of rosuvastatin to remove impurities from the reaction mixture. If active carbon is used during the conversion of rosuvastatin into its pharmaceutically acceptable salt, the active carbon may be used before or after contacting rosuvastatin with an alkali metal.
- the conversion of rosuvastatin into its pharmaceutically acceptable salt may also include filtering the reaction mixture.
- the reaction mixture may be filtered, such as with Synter and Hyflo ® , before or after washing with a water immiscible organic solvent.
- Wiped Film Evaporator made by Pope.
- DMMP (25.57 g) was dissolved in dry THF (140 mL) and the solution was cooled to - 75 0 C.
- n-BuLi 2.5M in hexane, 73.3 mL was added dropwise, keeping the temperature below -7O 0 C.
- the mixture was stirred at -70-75 0 C for 3h.
- Hydroxy- MBSG (10 g) was added in 4 portions every half an hour.
- THF (10 mL) was used to wash traces of hydroxy MBSG from the syringe. After stirring for 2h at -70-75 0 C, the mixture was quenched with AcOH (12 mL) and EtOAc (100 mL).
- Hydroxy-MBSG (OH-MBSG) can be obtained by enzymatic reaction of dimethylhydroxyglutarate and esterification according to WO 03/087112, incorporated by inference.
- the mixture was then extracted with toluene (3000 mL) and stirred at RT for half an hour. An aqueous phase formed and was isolated. The aqueous phase was concentrated under reduced pressure at 40° C. to half of the volume. Half of the remaining aqueous phase was transferred to a 500 mL reactor and water (110 mL) was added, creating a solution. The solution was stirred at RT for 5 minutes. Ca(OAc) (8.8 g) was added dropwise to t he solution over 117 min. at RT. The solution was stirred at RT for 1 hour, filtered, and washed with 60 mL of water, yielding a powdery compound (26 g, 94%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are processes and intermediates for preparation of rosuvastatin.
Description
ROSUVASTATIN INTERMEDIATES AND THEIR PREPARATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This application claims the benefit of U.S. Provisional Application No.
60/997,446, filed October 2, 2007, and 61/126,638, filed May 5, 2008. The contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
[002] The invention relates to new synthesis of Rosuvastatin intermediates.
BACKGROUND OF THE INVENTION
[003] Complications of cardiovascular disease, such as myocardial infarction, stroke, and peripheral vascular disease account for half of all deaths in the United States. A high level of low density lipoprotein (LDL) in the bloodstream has been linked to the formation of coronary lesions which obstruct the flow of blood and promote thrombosis. (See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9th ed., p. 879 (1996)). Reducing plasma LDL levels has been shown to reduce the risk of clinical events in patients with cardiovascular disease and in patients who are free of cardiovascular disease but who have hypercholesterolemia. (Scandinavian Simvastatin Survival Study Group, 1994; Lipid Research Clinics Program, 1984a, 1984b.)
[004] Statin drugs are currently the most therapeutically effective drugs available for reducing the level of LDL in the blood stream of a patient at risk for cardiovascular disease.
[005] The mechanism of action of statin drugs has been elucidated in some detail. The statin drugs disrupt the synthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme ("HMG-CoA reductase"). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. Consequently, HMG-CoA reductase inhibition leads to a reduction in the rate of formation of cholesterol in the liver. Decreased production of
cholesterol causes an increase in the number of LDL receptors and corresponding reduction in the concentration of LDL particles in the bloodstream. Reduction in the LDL level in the bloodstream reduces the risk of coronary artery disease. (J. A.M. A. 1984; 251 : 351-74).
[006] Currently available statins include: inter alia, compactin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin and atorvastatin, which are administered in their lactone form, as sodium salts, or as calcium salts.
[007] Rosuvastatin (7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino) pyrimidin-5-yl]-(3R, 5S)-dihydroxy-(E)-6-heptenoic acid) calcium, an HMG-CoA reductase inhibitor, can lower LDL-cholesterol and triglycerides levels more effectively than first generation statin drugs. Rosuvastatin calcium has the following chemical formula:
Rosuvastatin calcium
[008] A number of processes for the preparation of rosuvastatin and salts thereof are disclosed. Rosuvastatin calcium, intermediates of rosuvastatin, and their preparation are disclosed in U.S. Patent No. 5,260,440, herein the '440 patent. PCT publication No. WO 03/097614 discloses the synthesis of rosuvastatin from the late intermediate methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenyl- phosphoranylidene hexanate, an intermediate disclosed in the '440 patent. PCT publication No. WO 00/49014 discloses the synthesis of rosuvastatin using intermediates with other side chains via a Wittig reaction. EP 850,902 discloses the removal of triphenylphosphine derivatives in mixtures.
[009] PCT publication No. WO 06/091771 describes the synthesis of rosuvastatin calcium according to the scheme provided below:
Ci7H34O5Si C15H30O5Si ToI. CIeH34O7Si
346.53 318.48 390.54
17TB 18TB
BuLi
C34H45O4PSi THF 576.77
19TPPH
Ci6Hi8FN3O3S C32H48FN3O6SSi C26H34FN3O6S 351.39 649.89 535.63
14 or FPP-aldehyde 20TB 21TB
C26H36FN3O6S C44H54F2N6O12S2Ca 537.64 1001.13
TBRE ROSU
PCT publication No. WO 03/087112 discloses the synthesis of rosuvastatin from an intermediate t-butyl (3R)-3-(t-butyldimethylsilyloxy)-6-dimethoxyphosphinyl-5- oxohexanate ("19TBP0"). This process describes the preparation of t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R)-3-hydroxy-5-oxo-6-heptenate ("TB21"), a key intermediate in the preparation of rosuvastatin, by going through 19TBP0 intermediate. The process is illustrated in the following scheme:
OH
TBRE ROSU
[0010] Other intermediates and their preparation are also described in US patent numbers 5,354,879 and 5,717,124, which disclose the preparation of intermediate 19TBPO or ester analogs using purification by column chromatography
[0011] Like any synthetic compound, rosuvastatin calcium can contain extraneous compounds or impurities that can come from many sources. These can include unreacted starting materials, by-products of the reaction, products of side reactions, or degradation products. Impurities in rosuvastatin or any active pharmaceutical ingredient (API) are undesirable, and, in extreme cases, might even be harmful to a patient being treated with a dosage form of the API in which a sufficient amount of impurities are present.
[0012] There remains a need in the art for cost effective, industrial scale processes and shorter processes for the preparation of rosuvastatin intermediates.
SUMMARY OF THE INVENTION hi one embodiment, the present invention encompasses a non protected hydroxyl group intermediate, 19 OH-XYPO, having the following formula:
wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, aryl, and alkyl aryl group, preferably 19 OH-TBPO, having the following formula:
19 OH-TBPO
[0013] hi another embodiment, the present invention encompasses a process for preparing 19 OH-XYPO (particular Iy 19 OH-TBPO), comprising combining a compound, 19-0H-MBSG-XY, having the following formula:
preferably OH-MBSG, having the following formula:
OH Meθ2C^^^^CO2C4H9
OH-MBSG dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP.
[0014] hi another embodiment, the present invention provides a process for preparing 19 0H-XYP0 (particularly 19 OH-TBPO) and further converting it to TB21 and/or rosuvastatin and pharmaceutically accepted salts thereof.
[0015] In another embodiment the present invention provides a compound,
OH-MBSG-XY, having the following formula:
OH-MBSG-XY wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, aryl, and alkyl aryl group, preferably OH-MBSG, wherein the compound has a purity of at least about 95.5 % as measured by GC method.
[0016] hi another embodiment, the present invention provides a process for preparing OH-MBSG-XY (particularly OH-MBSG) and further converting it to TB21 and/or rosuvastatin and pharmaceutically accepted salts thereof.
[0017] In another embodiment, the present invention also provides a process for purifying OH-MBSG and/or 19 OH-TBPO by using a thin film evaporator, more preferably a thin wiped-fϊlm evaporator
In another embodiment, the present invention encompasses a process for preparing compound TB21 by a Wittig-Horner reaction comprising combining 19 OH-XYPO (particularly 19 OH-TBPO), FPP-aldehyde and a base.
[0018] In another embodiment, the present invention encompasses a process for preparing TB21 having the following formula:
TB21 comprising combining OH-MBSG, dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl
group intermediate 19 OH-TBPO; and combining the obtained 19 OH-TBPO with FPP-aldehyde and a base.
[0019] In another embodiment, the present invention a process for preparing
TB21 and further converting it to rosuvastatin and pharmaceutically accepted salts thereof.
[0020] In another embodiment, the present invention a process for purifying a one or more of rosuvastatin intermediates 19 OH -XYPO of formula:
Wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, aryl, and alkyl aryl group comprising applying a force under pressure of less than one atmosphere to increase surface area of a feed containing the intermediate, thereby providing the intermediate in purified form. In one embodiment the process comprises feeding the intermediate to a thin film evaporator is used. In one embodiment the process comprises feeding the intermediate to a thin film evaporator with wiper blades. Preferably X is O and Y is t-butyl.
[0021] In another embodiment, the present invention a process for preparing
TB21 and further converting it to rosuvastatin and pharmaceutically accepted salts thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0022] As used herein, the term "Wittig-Horner" refers to a condensation reaction of an aldehyde with a phosphonate derivative to create a double bond (also known as a Horner-Wadsworth-Emmons reaction). (See -Maryanoff et al. "The Wittig olefination reaction", Chem. Rev. (1989) 89, 863-927; Boutagy et al. "Olefin synthesis with organic phosphonate carbanions", Chem. Rev. (1974), 74 (1), 87-99; Wadsworth et al." The utility of phosphonate carbanions in olefin synthesis", JACS
(1961), 83, 1733-1738; Tsuge et al. "Horner-Emmons Olefination", Bull. Chem. Soc. Jpn. (1987), 60, 4091-4098.).
[0023] As used herein, the term room temperature (RT) refers to a temperature of about 200C to about 27°C.
[0024] As used herein, the term "OH-MBSG" refers to (R)-l-tert-butyl 5- methyl 3-hydroxypentanedioate having the following formula:
OH Meθ2C^^\^CO2C4H9
OH-MBSG
[0025] As used herein, the term "19 OH-TBPO" refers to the intermediate
(R)-butyl 5-(methoxycarbino)-2-hydroxy-4-oxopentanoate having the following formula:
19 OH-TBPO
[0026] As used herein, the term "FPP-aldehyde" refers to 4-(4-fluorophenyl)-
6-isopropyl-2-(N-methyl-N-methylsulfonylamino) pyrimidine, having the following formula:
FPP-aldehyde
[0027] As used herein, the term " TB21 " refers to t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R)-3-hydroxy-5-oxo-6-heptenate, having the following formula:
TB21
[0028] As used herein, the term "TBRE" refers to t-butyl-7-[4-(4- fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-yl]- (3R,5S)-3,5-dihydroxy-6-heptenate, having the following formula:
As used herein, "19 OH -XYPO" refers to the compound of formula:
wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, aryl, and alkyl aryl group.
As used herein, "OH-MBSG-XY" refers to the compound of formula:
wherein X is O, N, or S, and selected from the group consisting of: a Ci-C4 alkyl, aryl, and alkyl aryl group,
The present invention encompasses a non protected hydroxyl group intermediate, 19 OH-XYPO having the following structure:
wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, C6-Ci2 aryl, and C6-Ci2 alkyl aryl group. Preferably X is O and Y is a C]-C4 alkyl group, more preferably, Y is a t-butyl ester, providing 19 OH-TBPO, with the following formula:
19 OH-TBPO
An actual NMR of this compound was taken that confirmed the presence of this compound. An approximate NMR of this compound is disclosed in the example.
[0029] 19 OH -XYPO, particularly 19 OH-TBPO, is a key intermediate in the preparation of rosuvastatin calcium. The intermediate 19 OH-TBPO is a transparent to yellowish oil that cannot be purified by conventional scalable methods, such as crystallization.
[0030] In addition, 19 OH-TBPO decomposes at high temperatures of about
10O0C, and therefore cannot be purified by conventional distillation. Removing the impurities by conventional distillation without causing decomposition would require maintaining 19 OH-TBPO under low pressure of less than about 0.3 mm Hg and high temperature of about 12O0C. These requirements render conventional distillation methods inappropriate for the purification of large scale quantities of 19 OH-TBPO, and therefore conventional distillation of 19 OH-TBPO is not industrially applicable.
The invention provides a process for the purification of rosuvastatin intermediates, OH-MBSG-XY (particularly OH-MBSG) and/or 19 OH-XYPO (particularly 19 OH- TBPO), wherein the process is suitable for industrial use, as it does not entail chromatography steps. This process includes distilling the impurities of 19 OH-TBPO
and OH-TBPO with a thin film evaporator (TFE) device. The lack of need for protection/deprotection makes the process much shorter.
[0031] The use of a thin film evaporator allows a temperature increase during the distillation process without decomposition of OH-MBSG-XY (particularly OH- MBSG) and/or 19 OH-XYPO (particularly 19 OH-TBPO), allowing the preparation of pure materials.
[0032] A typical thin-film evaporator comprises of two major assemblies: a heated body and a close-clearance rotor. A feed travels to a rotating distributor plate. The feed can be from the top, which would then fall naturally by gravity onto the plate.
[0033] Optional Wiper blades, along with centrifugal force, resulting from the rotation of the plate, then create a thin film by distributing the feed, optimally evenly, over the wall. Due to reduced pressure in the plate chamber and the resulting increase, in surface area, the volatile components readily evaporate. The remaining "pure"solid is pushed to the sides by the blades and collected.
[0034] The feed is typically in the form of an oil which is obtained by removing the solvent in which OH-MBSG-XY (particularly OH-MBSG) and/or 19 OH -XYPO (particularly 19 OH-TBPO) is in. The feed can also be in the form of a solution. The solvent is typically removed in an evaporator, which leaves the oil (without solvent), hi principle, in a scale-up apparatus, these two operations (evaporation of solvent and then purification of the oil) can be done in the TFE. There can be a first rotating distributor plate, above a second plate, and the first and second plates can be heated at different temperatures.
[0035] In one embodiment the OH-MBSG-XY (particularly OH-MBSG) is purified by the TFE method. In this method OH-MBSG-XY (particularly OH-MBSG) is fed into the thin film evaporator, and the evaporation is performed at a temperature of about 1300C to about 2000C, more preferably of about 1500C to about 1600C. Preferably, the evaporation is performed under a pressure of about 0 mbar to about 15 mbar, more preferably of about 0.5 mbar to about 5 mbar, yet more preferably of about 0.97 mbar to about 1.2 mbar.
[0036] Preferably, the OH-MBSG-XY (particularly OH-MBSG) obtained by the thin film evaporation method of the invention has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area by GC. Preferably, the obtained OH-MBSG has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
[0037] The present invention provides OH-MBSG-XY (particularly OH-
MBSG) having a purity of at least about 90%, more preferably of at least about 95 %, and even more preferably of at least about 98 % area by GC. Preferably, OH-MBSG- XY (particularly OH-MBSG)has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area as measured by GC. Preferably, the OH-MBSG-XY (particularly OH-MBSG)has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
[0038] In one embodiment, the 19 OH -XYPO (particularly 19 OH-TBPO) is purified by the TFE method. In this method 19 OH -XYPO (particularly 19 OH- TBPO) is fed into the thin film evaporator, and the evaporation is performed at a temperature of about 130°C to about 2000C, more preferably of about 150°C to about 160°C. Preferably, the evaporation is performed under a pressure of about 0 mbar to about 15 mbar, more preferably of about 0.97 mbar to about 1.2 mbar.
[0039] Preferably, the OH-MBSG-XY (particularly OH-MBSG) and/or 19
OH -XYPO (particularly 19 OH-TBPO) obtained by the thin film evaporation method of the invention has a purity of at least about 95.5 %, more preferably of at least about 98.4 %, and even more preferably of at least about 99.5 % area as measured by GC. Preferably, the obtained 19 OH-TBPO has an assay purity of at least about 98.4 %, more preferably of at least about 99 %, and most preferably of at least about 100 % w/w.
[0040] The present invention provides a process of purifying OH-MBSG-XY
(particularly OH-MBSG) and/or 19 OH -XYPO (particularly 19 OH-TBPO) and further converting them to Rosuvastatin.
[0041 ] The 19 OH -XYPO (particularly 19 OH-TBPO) can be prepared by a process comprising combining a compound OH-MBSG-XY (particularly OH-MBSG, having the following formula:
OH-MBSG ), dimethylmethylphosphonate (DMMP), and a base capable of making a carbanion on DMMP, as exemplified in the scheme provided below:
wherein M is the metal counter ion of the base. Similarly 19 OH -XYPO can be prepared from OH-MBSG-XY.
[0042] The process can be carried out by dissolving DMMP in an organic solvent that is inert to a strong base, and adding dropwise or slowly a base that is sufficiently strong to produce a carbanion. Examples of such bases include LDA, sodium or lithium salts of Hexamethyldisilazane, sec-BuLi, tert-BuLi, NaH, KH, KtBuO, NaBuO, and C4 to Cjo alkyl lithium. Preferably, the organic solvent is selected from the group consisting of: dimethoxyethane ("DME"), hexane, methylene chloride tetrahydrofuran ("THF") and dioxane. More preferably, the organic solvent is THF, most preferably, dry THF (contains less than 2% water by volume). The solution can be cooled, such as to a temperature of about -50°C to about -100°C, more preferably, to a temperature of about -75°C.
[0043] The base capable of making a carbanion on DMMP is preferably BuLi.
Preferably, n-BuLi is added to the solution to obtain a reaction mixture. The reaction mixture can be maintained at a temperature of about -500C to about -10O0C. More preferably, the reaction mixture is maintained at a temperature of about -7O0C to about- 1000C. Preferably, n-BuLi is dissolved in hexane.
[0044] A base is used to allow formation of the carbanion reaction to occur.
Preferably, the base after reaction provide a metal cation (M+) that is selected from the group consisting of lithium, sodium, potassium and cesium. More preferably, M+ is lithium to the base used for the preparation of the phosphonate.
[0045] OH-MBSG-XY (particularly OH-MBSG) can be combined with the reaction mixture in 4 portions. Preferably, OH-MBSG-XY (particularly OH-MBSG) is added in intervals of about 5 minutes to about 60 minutes, more preferably, in intervals of about 30 minutes on gram scale.
[0046] Prior to the addition of OH-MBSG-XY (particularly OH-MBSG), the reaction mixture can be stirred. The stirring can be done at a temperature of about - 50°C to about -100°C, more preferably, at a temperature of about -70°C to about - 750C. The stirring can be for about 1 hour to about 6 hours, more preferably, for about 3 hours.
[0047] The reaction mixture can be washed to remove impurities. The washing can be with the same solvent used during the process.
[0048] After a washing step, if carried out, the reaction mixture can be stirred.
The stirring is at a temperature of about -50°C to about -100°C. Preferably, at a temperature of about -700C to about -75°C. Preferably, the stirring is for about 2 hours.
[0049] The reaction mixture can be quenched by adding an agent that has an available proton. The quenching may be done using water, organic acid or inorganic acid. Preferably, the quenching is with AcOH and EtOAc. The reaction mixture can be heated to bring the temperature to about -10 to about 300C, such as about room temperature or a temperature of about 200C, before separation. Water can be added to the heated reaction mixture to obtain a two phase system in order to perform the extraction of 19 OH -XYPO (particularly 19 OH-TBPO).
[0050] For extraction, the two phases are separated. The aqueous phase is extracted. The extraction can be done with polar solvents such as CH2Cl2, Diethylcarbonate, Methyl ethyl ketone, Methyl iso-butyl ketone,
cyclopenthylmethylether, t-buteyl methyl ether, diethyl ether, diisopropylether, more preferably with EtOAc (ethyl acetate).
[0051] Optionally, the organic layer is dried and filtered. Preferably, the drying is done with dehydrating reagent or molecular sieves, more preferably, with a dehydrating reagent. Preferably, the dehydrating reagent is sodium sulfate (Na2SO4) or magnesium sulfate (MgSO4), more preferably Na2SO4
[0052] The obtained dried and filtered layer is further concentrated to obtain a residue of 19 OH -XYPO (particularly 19 OH-TBPO). Preferably, the concentration is under a pressure of less than one atmosphere, or a pressure of less than 1 OOmmHg, such as in a vacuum. Preferably, the concentration is done by vacuum distillation. Preferably, the vacuum distillation is done whilst heating, such as to a temperature of about 2O0C to about 9O0C.
[0053] Preferably, the obtained non protected hydroxyl group intermediate, 19
OH -XYPO (particularly 19 OH-TBPO), is further purified by a thin film evaporator. In a large scale apparatus, both concentrations of 19 OH -XYPO (particularly 19 OH- TBPO) after extraction and purification could be performed in a TFE.
[0054] 19 OH -XYPO (particularly 19 OH-TBPO) obtained by the processes of the invention may be further used to prepare rosuvastatin and pharmaceutically accepted salts thereof, for example, according to the procedures described in PCT publication No. WO 06/091771.
[0055] The 19 OH -XYPO (particularly 19 OH-TBPO),obtained, optionally by the thin film evaporation purification, can be converted to TB21 (or another ester) by a Wittig-Horner reaction. The process for preparing compound TB21 by a Wittig- Horner reaction comprises combining 19 OH-TBPO, FPP-aldehyde and a base,
[0056] Prior to the process, 19 OH -XYPO (particularly 19 OH-TBPO) can be dissolved in a dry solvent (contain less than 2% water by volume). Examples of dry solvents include, but are not limited to, ethereal solvents such as tetrahydrofuran ("THF"), dioxane, dimethoxyethane ("DME"), aromatic solvents such as toluene, chlorinated solvents and acetonitrile. More preferably, the solvent is dry THF. The solution can be cooled, such as to a temperature of about -200C to about 1O0C, more preferably to about O0C.
[0057] Suitable bases for the Wittig-Horner reaction, include but are not limited to, metal hydrides, MOMe, MOH, MOtBu, M2CO3, wherein M can be sodium, potassium, lithium or cesium, BuLi or other lithiated bases, DBU (1,8- diazabicyclo[5.4.0]undec-7-ene), and DABCO (diazabicyclo[2.2.2]octane).. Preferably, the base is KOtBu. The base is preferably added to the cooled solution to obtain a reaction mixture. The base can be added under stirring. The reaction mixture can be stirred at a temperature of about -200C to about 400C, more preferably at about O0C. The reaction mixture can be further stirred. The stirring can be for about 1 minute to about 1 hour, more preferably for about 15 minutes.
[0058] In one embodiment, FPP-aldehyde is added to the reaction mixture.
After the addition of FPP-aldehyde, the reaction mixture can be stirred, such as at a temperature of about O0C to about 6O0C, more preferably at about 4O0C. The mixture can be stirred for about 1 hour to about 12 hours, such as about 7 hours.
[0059] After completion of the reaction, the reaction can be quenched, such as by using an acid, including AcOH (acetic acid). The reaction mixture can be optimized for recovery of the product, by adding water (and optionally brine) and a water immiscible organic solvent such as ethyl acetate to obtain two phases.
[0060] The phases can be then separated. The organic phase can be washed such as with water or saturated bicarbonate and brine, hi one embodiment, the washing is done with saturated bicarbonate and brine.
[0061] Following the phases separation, the remaining solvent is removed to obtain TB21. Preferably, the removal of the solvent is under pressure of less than one atmosphere, such as vacuum (less than lOOmmHg).
[0062] In one embodiment, the compound TB21 :
TB21 is prepared by a process comprising combining OH-MBSG having the following formula:
OH
Meθ2C^/^/Cθ2C4H9
OH-MBSG
DMMP and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl group intermediate 19 OH-TBPO having the following formula:
19 OH-TBPO and combining the obtained 19 OH-TBPO with FPP-aldehyde and a base. [0063] TB21 obtained by the processes of the invention may be further converted to rosuvastatin and pharmaceutically accepted salts thereof. The conversion may be done according to PCT publication No. WO 06/091771 and according to US RE37,314. The procedure described in PCT publication No. WO 06/091771 includes converting TB21 to rosuvastatin through the intermediate TBRE. TBRE is obtained by a reduction of the intermediate TB21 according to the scheme provided below:
This process can be performed using diethylmethoxyborane in THF and sodium borohydride. Rosuvastatin may be obtained upon saponification of TBRE according to the scheme provided below:
TBRE Rosuvastatin
[0064] The processes of the present invention may be illustrated in the following scheme:
OH
MeO2C~^^v^-CO2C4H9
OH-MBSG
19 OH-TBPO
[0065] Rosuvastatin obtained by the processes of the invention may be further converted to a pharmaceutically acceptable salt of rosuvastatin, preferably the calcium salt. [See e.g. U.S. patent No. 5,260,440]. The process of converting rosuvastatin into its pharmaceutically acceptable salt includes contacting rosuvastatin with calcium hydroxide, or with a stronger base such as sodium hydroxide. The base is preferably combined dropwise with a reaction mixture of rosuvastatin at a suitable temperature, such as a temperature of about 25°C ± 5°C. The reaction mixture may be washed with a suitable water immiscible organic solvent. Suitable water immiscible organic solvents include, but are not limited to, hydrocarbons; preferably the water immiscible organic solvent is toluene. The water immiscible organic solvent may be removed by phase separation. Remaining water immiscible organic solvent may be removed by distillation of the reaction mixture, preferably at a temperature of about 400C to about 45°C under reduced pressure (below about 50 mmHg).
Column & Packing : DB- 17 30m x 0.53mm lμm film thickness
[0066] The reaction mixture may then be combined with an alkali metal, including a source of calcium such as calcium chloride or calcium acetate, to form the salt of rosuvastatin. [See e.g. U.S. patent No. 6,777,552]. For example, calcium chloride may be added dropwise to a reaction mixture of rosuvastatin at a suitable temperature, such as a temperature of about 350C to about 450C, and preferably at about 40°C, over a period of about thirty to about ninety minutes. Active carbon may be combined with a reaction mixture of rosuvastatin to remove impurities from the reaction mixture. If active carbon is used during the conversion of rosuvastatin into its pharmaceutically acceptable salt, the active carbon may be used before or after contacting rosuvastatin with an alkali metal.
[0067] The conversion of rosuvastatin into its pharmaceutically acceptable salt may also include filtering the reaction mixture. The reaction mixture may be filtered, such as with Synter and Hyflo®, before or after washing with a water immiscible organic solvent.
[0068] Having thus described the invention with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification. The Examples are set forth to aid in understanding the invention but are not intended to, and should not be construed to, limit its scope in any way. Absent statement to the contrary, any combination of the specific embodiments described above are consistent with and encompassed by the present invention.
Instrumental:
Wiped Film Evaporator made by Pope.
0.02 m2 heat transfer area, 50mm diameter, made in glass with three Teflon wipers
GC method:
Injector temperature 180°C
Detector temperature 3000C
Oven temperature 40°C for 3 minutes, than 20°C/minute up to 160°C, than 1600C for 10 minutes, than 10°C/minute up to 210°C, than 2100C for
10 minutes, than 20°C/minute up to 2700C for 10 minutes.
Injection volume 1.0 μl
Flow 10 ml/min Helium at 400C Mode Constant flow Split ratio 1 :10 Detector FID
Diluent Acetonitrile
Standard solution preparation
Weigh accurately 20mg of 19TBPO standard into 10ml volumetric flask, dissolve and bring to volume with Diluent.
Sample solution preparation
Weigh accurately 20mg of 19TBPO sample into 10ml volumetric flask, dissolve and bring to volume with Diluent.
Procedure
Inject the standard and sample solutions continuing the chromatogram up to the end of gradient.
EXAMPLES
Example 1 : Preparation of 19 OH-TBPO
DMMP (25.57 g) was dissolved in dry THF (140 mL) and the solution was cooled to - 750C. n-BuLi (2.5M in hexane, 73.3 mL) was added dropwise, keeping the temperature below -7O0C. The mixture was stirred at -70-750C for 3h. Hydroxy- MBSG (10 g) was added in 4 portions every half an hour. THF (10 mL) was used to wash traces of hydroxy MBSG from the syringe. After stirring for 2h at -70-750C, the mixture was quenched with AcOH (12 mL) and EtOAc (100 mL). The mixture was heated to 2O0C and water (100 mL) was added. Layers were separated and the water layer was extracted with EtOAc (100 mL, 4 times). Combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum. The residue contained more than 30% of DMMP, which was removed by vacuum distillation (3 mbar) upon heating of the residue to 80-900C. The residue (12.1 g) contained 81.2% 19 OH- TBPO (yield 69%).
1H NMR (300 MHz, CDCl3): δ 1.40 (s, 9H), 2.85 (d, 2H, J=6 Hz), 2.40 (d, 2H, J=6Hz), 3.10 (d, 2H, J=23 Hz), 3.75 (d,6H), 4.50 (m, IH) (approximate).
Hydroxy-MBSG (OH-MBSG) can be obtained by enzymatic reaction of dimethylhydroxyglutarate and esterification according to WO 03/087112, incorporated by inference.
Example 2:
2Og 19-OHTBPO residue (purity GC 63.4%) is purified by thin film evaporator (TFE) atl50°C under 1.2 mbar vacuum to get 11.6g 19-OHTBPO (Purity GC 95.5% area, assay 98.4%w/w).
Example 3: Preparation of TB21 from 19 OH-TBPO
Solution of 19 OH-TBPO (2.17 g, assay 92%) in THF (10 mL) was cooled to O0C. KOtBu (0.67g) was added under stirring. The mixture was stirred at O0C for 15 min and FPP-aldehyde (1.5Ig) was added. The mixture was stirred at 400C for 7h and quenched with AcOH (0.15 mL). Brine (15 mL) and EtOAc (30 mL) were added. Phases were separated. The organic phase was washed with saturated bicarbonate solution (15 mL) and brine (15 mL). The solvent was removed under vacuum, resulting in crude TB-21 (2.99 g, assay 46%, yield 60%).
Example 4: Conversion of Compound TBRE into Rosuvastatin Ca with Extraction in Toluene
A l L reactor equipped with a mechanical stirrer was charged with EtOH (300 mL), water (90 ml), and 22TB (60 g), forming a reaction mixture. NaOH (47% 1.2eq, 11.4 g) was added dropwise to the reaction mixture at RT. The reaction mixture was stirred at about RT for two hours. The reaction mixture was filtered under reduced pressure with Synter and Hyflo® to eliminate the small particles present. Water (420 ml) was added to the reaction mixture.
The mixture was then extracted with toluene (3000 mL) and stirred at RT for half an hour. An aqueous phase formed and was isolated. The aqueous phase was concentrated under reduced pressure at 40° C. to half of the volume. Half of the remaining aqueous phase was transferred to a 500 mL reactor and water (110 mL) was added, creating a solution. The solution was stirred at RT for 5 minutes. Ca(OAc) (8.8 g) was added dropwise to t he solution over 117 min. at RT. The solution was stirred at RT for 1 hour, filtered, and washed with 60 mL of water, yielding a powdery compound (26 g, 94%).
Claims
1. A compound, 19 OH-XYPO, of the following formula:
2. The compound of claim 2, wherein the compound is:
19 OH-TBPO
3. The compound of any one of claim 1-2, wherein the compound has a purity of at least about 95.5 % as area measured by GC.
4. The compound of any one of claim 1 -3, wherein the compound has a purity of at least about 98.4%.
5. The compound of any one of claim 1 -4, wherein the compound has a purity of at least at least about 99.5 % area as measured by GC.
6. The compound of any one of claim 1-5, wherein the compound has an assay purity of at least about 98.4% w/w.
7. The compound of any one of claim 1-6, wherein the compound has an assay purity of at least at least about 99% w/w.
8. The compound of any one of claim 1-7, wherein the compound has an assay purity of at least about 1 OO % w/w.
9. A process for preparing compound of claim 1-8 comprising combining compound, 19-OH-MBSG-XY, having the following formula: wherein X is O, N, or S, and Y is selected from the group consisting of: a Cj-C4 alkyl group, C6 to Ci2 aryl, and C6 to Ci2 alkyl aryl with dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP.
OH-MBSG
11. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising converting compound obtained by the process of claim 9-10 to rosuvastatin or a pharmaceutically accepted salts thereof.
12. The process of any one of claim 9-11, wherein the process comprises combining OH-MBSG, dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl group intermediate 19 OH-TBPO; and combining the obtained 19 OH-TBPO with FPP- aldehyde and a base.
13. A process for preparing compound TB21
14. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising converting TB21 prepared in claim 13 to rosuvastatin or a pharmaceutically acceptable salt.
16. The compound of claim 15, wherein the compound is:
OH MeO2C^^^CO2C4H9
OH-MBSG
17. The compound of any one of claim 15-16, wherein the compound has a purity of at least about 98.4 %.
18. The compound of any one of claim 17, wherein the compound has a purity of at least at least about 99.5 % area by GC.
19. The compound of any one of claim 15-18, wherein the compound has an assay purity after purification of at least about 98.4% w/w.
20. The compound of any one of claim 19, wherein the compound has an assay purity after purification of at least at least about 99% w/w.
21. The compound of any one of claim 20, wherein the compound has an assay purity after purification of at least about 100 % w/w.
22. A process for preparing compound, 19 OH-XYPO, of the following structure:
23. The process of claim 22, wherein the base is LDA, sodium or lithium salts of Hexamethyldisilazane, sec-BuLi, tert-BuLi, NaH, KH, KtBuO, NaBuO, and C4 to Cio alkyl lithium.
24. The process of any one of claim 22-23, wherein an organic solvent is used that is selected from the group consisting of: dimethoxyethane ("DME"), hexane, methylene chloride tetrahydrofuran ("THF") and dioxane.
25. The process of any one of claim 24, wherein the organic solvent is THF.
26. The process of any one of claim 22-25, wherein combining is carried out at a temperature of about -5O0C to about -1000C.
27. The process of any one of claim 22-26, wherein the base is BuLi.
28. The process of any one of claim 22-27, wherein the compound is:
19 OH-TBPO
29. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising converting compound obtained by the process of claim 22 to rosuvastatin or a pharmaceutically accepted salts thereof.
30. A process for preparing compound TB21
31. The process of any one of claim 30, wherein the process comprises combining OH-MBSG, dimethylmethylphosphonate (DMMP) and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl group intermediate 19 OH-TBPO; and combining the obtained 19 OH-TBPO with FPP- aldehyde and a base.
32. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising converting TB21 prepared in claim 30-31 to rosuvastatin or a pharmaceutically acceptable salt.
33. A process for purifying a one or more of rosuvastatin intermediates 19 OH - XYPO of formula:
or OH-MBSG-XY of formula: wherein X is O, N, or S, and Y is selected from the group consisting of: a Ci-C4 alkyl, C6 to Ci2 aryl, and C6 to Cj2 alkyl aryl group, comprising applying a force under pressure of less than one atmosphere to increase surface area of a feed containing the intermediate, thereby providing the intermediate in purified form.
34. The process of claim 33, wherein the process comprises feeding the intermediate to a thin film evaporator.
35. The process of any one of claim 33-34, wherein the process comprises feeding the intermediate to a thin film evaporator with wiper blades.
36. The process of any one of claim 33-35, wherein the intermediate is 19 OH - XYPO having the formula:
37. The process of claim 36, wherein the intermediate is 19 OH-TBPO having the formula:
19 OH-TBPO
39. The process of claim 38, wherein the intermediate is OH-MBSG having the formula:
OH MeO2C^^^^Cθ2C4H9
OH-MBSG
40. The process of any one of claim 33-39, wherein the process is carried out at a temperature of about 1300C to about 2000C.
41. The process of claim 40, wherein temperature is about 1500C to about 1600C.
42. The process of any one of claim 33-41, wherein the process is carried out at a pressure of about 0 mbar to about 15 mbar.
43. The process of claim 42, wherein the pressure is about 0.97 mbar to about 1.2 mbar.
44. The process of any one of claim 33-43, wherein the intermediate after purification has a purity of at least about 95.5% area as measured as measured by GC.
45. The process of claim 44, wherein the intermediate after purification has a purity of at least about 98.4% area as measured by GC.
46. The process of claim 45, wherein the intermediate after purification has a purity of at least at least about 99.5% area as measured by GC.
47. The process of claim 33, wherein the intermediate has an assay purity after purification of at least about 98.4% w/w.
48. The process of claim 47, wherein the intermediate has an assay purity after purification of at least at least about 99% w/w.
49. The process of claim 48, wherein the intermediate has an assay purity after purification of at least about 100 % w/w.
50. The process of any one of claim 33-45, 38-49, wherein the obtained purified OH- MBSG-XY is further converted to 19 OH-XYPO.
51. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising purifying OH-MBSG-XY as in claim 33-35, 38-50, and converting it to rosuvastatin or a pharmaceutically acceptable salt.
52. A process for preparing compound TB21
53. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising purifying 19 OH -XYPO as in claim 33-50, and converting it to rosuvastatin.
54. A process for preparing rosuvastatin or a pharmaceutically acceptable salt thereof comprising, first purifying OH-MBSG-XY as in claim 33-50 and using the purified OH-MBSG to synthesize 19 OH -XYPO, followed by purification of 19 OH -XYPO, as in claim 33-50 and conversion of purified 19 OH -XYPO to rosuvastatin or a pharmaceutically acceptable salt thereof.
55. The process of claim 54, wherein 19 OH-XYPO is prepared by combining OH- MBSG-XY with a base, a solvent and DMMP.
56. The process of claim 55, wherein an organic solvent is used that is selected from the group consisting of: dimethoxyethane ("DME"), hexane, methylene chloride tetrahydrofuran ("THF") and dioxane.
57. The process of claim 56, wherein the solvents is THF.
58. The process of claim 55, wherein the base is BuLi.
59. A process for preparing compound TB21 :
TB21 comprising combining OH-MBSG having the following formula:
OH MeO2C^/^^.CO2C4H9
OH-MBSG
DMMP and a base which is capable of making a carbanion on DMMP to obtain a non protected hydroxyl group intermediate 19 OH-TBPO having the following formula:
19 OH-TBPO and combining the obtained 19 OH-TBPO with FPP-aldehyde and a base.
60. Use of the process or compound of any of the preceding claims in the preparation of rosuvastatin, rosuvastatin calcium or TB21.
61. The process or compound of any of the preceding claims wherein X is O, and Y is selected from the group consisting of: a Ci-C4 alkyl, preferably t-butyl.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010516074A JP2010533188A (en) | 2007-07-12 | 2008-07-14 | Lovastatin intermediate and process for producing the same |
EP08780195A EP2178846A1 (en) | 2007-07-12 | 2008-07-14 | Rosuvastatin intermediates and their preparation |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95938307P | 2007-07-12 | 2007-07-12 | |
US60/959,383 | 2007-07-12 | ||
US96287907P | 2007-07-31 | 2007-07-31 | |
US60/962,879 | 2007-07-31 | ||
US99744607P | 2007-10-02 | 2007-10-02 | |
US60/997,446 | 2007-10-02 | ||
US6909808P | 2008-03-11 | 2008-03-11 | |
US61/069,098 | 2008-03-11 | ||
US12663808P | 2008-05-05 | 2008-05-05 | |
US61/126,638 | 2008-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009009152A1 true WO2009009152A1 (en) | 2009-01-15 |
Family
ID=39842798
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/008635 WO2009009152A1 (en) | 2007-07-12 | 2008-07-14 | Rosuvastatin intermediates and their preparation |
PCT/US2008/008636 WO2009009153A1 (en) | 2007-07-12 | 2008-07-14 | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/008636 WO2009009153A1 (en) | 2007-07-12 | 2008-07-14 | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
Country Status (4)
Country | Link |
---|---|
US (2) | US20090069563A1 (en) |
EP (2) | EP2178890A1 (en) |
JP (2) | JP2010533188A (en) |
WO (2) | WO2009009152A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012093227A1 (en) | 2011-01-07 | 2012-07-12 | Jacquot Epouse Guilmin Liliane | Prodrugs for dispensing a statin to the liver |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2178890A1 (en) * | 2007-07-12 | 2010-04-28 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
CN102219749B (en) * | 2010-04-14 | 2013-07-17 | 上海京新生物医药有限公司 | Method for preparing rosuvastatin calcium |
WO2015074328A1 (en) * | 2013-11-25 | 2015-05-28 | 复旦大学 | Method for preparing rosuvastatin sodium |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US5354879A (en) | 1991-06-19 | 1994-10-11 | Shionogi Seiyaku Kabushiki Kaisha | Optically active intermediate and method for production thereof |
JPH07118233A (en) | 1993-10-19 | 1995-05-09 | Shionogi & Co Ltd | Production of pyrimidine derivative |
US5717124A (en) | 1993-03-30 | 1998-02-10 | Ube Industries, Ltd. | Process for preparation of oxyglutaric acid ester derivatives |
WO2003087112A1 (en) | 2002-04-09 | 2003-10-23 | Cls Laboratories, Inc. | Chiral intermediate and process for the production thereof |
WO2006091771A2 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
WO2007040940A1 (en) | 2005-10-03 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Diastereomeric purification of rosuvastatin |
WO2007041666A1 (en) | 2005-10-04 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001250A (en) * | 1989-05-30 | 1991-03-19 | Occidental Chemical Corporation | Purification of bidentate organophosphorous extractants |
JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
GB9626746D0 (en) | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
KR20040026705A (en) * | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | Processes for preparing calcium salt forms of statins |
KR20040081161A (en) * | 2002-01-31 | 2004-09-20 | 노파르티스 아게 | PROCESS FOR THE MANUFACTURE OF HMG-CoA REDUCTASE INHIBITORS |
GB0204129D0 (en) * | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
GB0210234D0 (en) * | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
AU2003228010A1 (en) | 2002-05-21 | 2003-12-02 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
SI1578733T1 (en) * | 2002-12-10 | 2011-07-29 | Ranbaxy Lab Ltd | Process for the preparation of rosuvastatin |
CA2657076A1 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
CN1886383A (en) * | 2003-10-22 | 2006-12-27 | 兰贝克赛实验室有限公司 | Process for the preparation of amorphous rosuvastatin calcium |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
CZ298330B6 (en) | 2004-07-19 | 2007-08-29 | Zentiva, A. S. | Process for preparing 4-(4--fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl-amino)-5-pyrimidinecarbaldehyde and use thereof |
CN1807417A (en) | 2005-01-18 | 2006-07-26 | 何如钧 | Novel waterless crystallization-free rosuvastatin calcium |
CN100351240C (en) * | 2005-01-19 | 2007-11-28 | 安徽省庆云医药化工有限公司 | Rosuvastatin calcium synthesis method |
US20070167625A1 (en) * | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
CN1307187C (en) | 2005-05-16 | 2007-03-28 | 浙江海正药业股份有限公司 | Method for preparing Rosuvastain and its intermediate |
US8207333B2 (en) | 2005-06-24 | 2012-06-26 | Lek Pharmaceuticals D. D. | Process for preparing pure amorphous rosuvastatin calcuim |
WO2006136407A1 (en) | 2005-06-24 | 2006-12-28 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
MX2007004423A (en) * | 2005-08-16 | 2007-06-14 | Teva Pharma | Rosuvastatin calcium with a low salt content. |
CN1958593B (en) | 2005-11-03 | 2010-05-05 | 上海医药工业研究院 | Method for preparing intermediate of synthesizing rosuvastatin calcium |
WO2007069264A2 (en) * | 2005-12-15 | 2007-06-21 | Alembic Limited | Reference standards for determining the purity of telithromycin and processes therefor |
CN1821242B (en) | 2006-02-16 | 2012-03-07 | 亚邦化工集团有限公司 | Novel method for preparing dihydroxy acid HMG CoA reductase inhibitor |
WO2007099561A1 (en) | 2006-02-27 | 2007-09-07 | Cadila Healthcare Limited | Process for preparing rosuvastatin calcium |
US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
EP2178890A1 (en) * | 2007-07-12 | 2010-04-28 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
-
2008
- 2008-07-14 EP EP08794498A patent/EP2178890A1/en not_active Withdrawn
- 2008-07-14 JP JP2010516074A patent/JP2010533188A/en active Pending
- 2008-07-14 JP JP2009526959A patent/JP2010501643A/en active Pending
- 2008-07-14 WO PCT/US2008/008635 patent/WO2009009152A1/en active Application Filing
- 2008-07-14 EP EP08780195A patent/EP2178846A1/en not_active Withdrawn
- 2008-07-14 US US12/218,402 patent/US20090069563A1/en not_active Abandoned
- 2008-07-14 WO PCT/US2008/008636 patent/WO2009009153A1/en active Application Filing
- 2008-07-14 US US12/218,403 patent/US7884226B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US5354879A (en) | 1991-06-19 | 1994-10-11 | Shionogi Seiyaku Kabushiki Kaisha | Optically active intermediate and method for production thereof |
US5717124A (en) | 1993-03-30 | 1998-02-10 | Ube Industries, Ltd. | Process for preparation of oxyglutaric acid ester derivatives |
JPH07118233A (en) | 1993-10-19 | 1995-05-09 | Shionogi & Co Ltd | Production of pyrimidine derivative |
WO2003087112A1 (en) | 2002-04-09 | 2003-10-23 | Cls Laboratories, Inc. | Chiral intermediate and process for the production thereof |
WO2006091771A2 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
WO2007040940A1 (en) | 2005-10-03 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Diastereomeric purification of rosuvastatin |
WO2007041666A1 (en) | 2005-10-04 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
Non-Patent Citations (8)
Title |
---|
ANDRUSHKO V ET AL: "Highly enantioselective catalytic hydrogenation of a 5-amino-3,5-dioxopentanoic ester", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 49, no. 33, 7 June 2008 (2008-06-07), pages 4836 - 4839, XP022819094, ISSN: 0040-4039 * |
BOUTAGY ET AL.: "Olefm synthesis with organic phosphonate carbanions", CHEM. REV., vol. 74, no. 1, 1974, pages 87 - 99 |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SIT, SING YUEN ET AL: "Preparation of tetrazolyldiarylalkenoates as hypocholesteremics", XP002497823, retrieved from STN Database accession no. 1990:611987 * |
GOODMAN, GILMAN: "The Pharmacological Basis of Therapeutics", 1996, pages: 879 |
HEATHCOCK, CLAYTON H. ET AL: "Total synthesis and biological evaluation of structural analogs of compactin and dihydromevinolin", JOURNAL OF MEDICINAL CHEMISTRY , 30(10), 1858-73 CODEN: JMCMAR; ISSN: 0022-2623, 1987, XP002218100 * |
MARYANOFF ET AL.: "The Wittig olefination reaction", CHEM. REV., vol. 89, 1989, pages 863 - 927, XP008146334, DOI: doi:10.1021/cr00094a007 |
See also references of EP2178846A1 * |
WADSWORTH ET AL.: "The utility of phosphonate carbanions in olefin synthesis", JACS |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012093227A1 (en) | 2011-01-07 | 2012-07-12 | Jacquot Epouse Guilmin Liliane | Prodrugs for dispensing a statin to the liver |
FR2970178A1 (en) * | 2011-01-07 | 2012-07-13 | Liliane Therese Jacquot | PROMOTERS FOR SPECIFIC LIVER LEVEL DELIVERY AND BETTER TOLERANCE |
Also Published As
Publication number | Publication date |
---|---|
US20090099383A1 (en) | 2009-04-16 |
JP2010533188A (en) | 2010-10-21 |
JP2010501643A (en) | 2010-01-21 |
US20090069563A1 (en) | 2009-03-12 |
WO2009009153A9 (en) | 2009-06-18 |
US7884226B2 (en) | 2011-02-08 |
EP2178846A1 (en) | 2010-04-28 |
EP2178890A1 (en) | 2010-04-28 |
WO2009009153A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2594017C (en) | Preparation of rosuvastatin | |
US20070037979A1 (en) | Preparation of rosuvastatin | |
JP6105467B2 (en) | Method for synthesizing entecavir and intermediate compound thereof | |
EP1863773A1 (en) | Process for preparation of rosuvastatin | |
WO2008053334A2 (en) | An improved process for preparing rosuvastatin calcium | |
US20070167625A1 (en) | Preparation of rosuvastatin | |
WO2009009152A1 (en) | Rosuvastatin intermediates and their preparation | |
KR101091130B1 (en) | Precursive compound of rosuvastatin and manufacturing method for the precursive compound of rosuvastatin | |
KR101045895B1 (en) | Preparation of rosuvastatin | |
US8653265B2 (en) | Preparation method of rosuvastatin calcium and its intermediates | |
US20110295005A1 (en) | Process for preparing pyrimidine derivatives | |
KR20140017207A (en) | Rosuvastatin isopropyl amine salt, the preparation method thereof and the preparation method of rosuvastatin hemicalcium salt using the same | |
EP0164049B1 (en) | Process for preparing hmg-coa reductase inhibtors with a 3,5-dihydroxypentanoate subunit | |
KR101164426B1 (en) | Precursor, intermediates and their salts of statin series for hyperlipemia and manufacturing method for them | |
KR20120092788A (en) | New statin intermediate, the preparation of the same and the preparation of rosuvastatin using the same | |
MX2007006647A (en) | Preparation of rosuvastatin. | |
EP2513065A1 (en) | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | |
KR20160126700A (en) | New Statin intermediate, the preparation of the same and the preparation of Rosuvastatin using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08780195 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010516074 Country of ref document: JP Ref document number: 158/DELNP/2010 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008780195 Country of ref document: EP |